Effect of Platelet Function Testing Guidance on Clinical Outcomes for Patients with Intracranial Aneurysms Undergoing Endovascular Treatment
American Journal of Neuroradiology · 2023
DOI: 10.3174/ajnr.a7923 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Neuroradiology, 2023. Verfasst von X Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: From the Departments of Pharmacy (X.W., Z.A.). Hauptthemen laut MEDLINE: Embolization, Therapeutic, Endovascular Procedures, Intracranial Aneurysm, Thromboembolism. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Platelet function testing has been proposed to better adjust individualized antiplatelet treatment for patients undergoing endovascular treatment for intracranial aneurysms. Its clinical significance needs to be comprehensively evaluated. PURPOSE: Our aim was to evaluate the impact of platelet function testing-guided versus standard antiplatelet treatment in patients receiving endovascular treatment for intracranial aneurysms. DATA SOURCES: PubMed, EMBASE, and the Cochrane Library of clinical trials were searched from inception until March 2023. STUDY SELECTION: Eleven studies comprising 6199 patients were included. DATA ANALYSIS: ORs with 95% CIs were calculated using random effects models. DATA SYNTHESIS: The platelet function testing-guided group was associated with a decreased rate of symptomatic thromboembolic events (OR = 0.57; 95% CI, 0.42-0.76; I2 = 26%). No significant difference was found in asymptomatic thromboembolic events (OR = 1.07; 95% CI, 0.39-2.94; I2 = 48%), hemorrhagic events (OR = 0.71; 95% CI, 0.42-1.19; I2 = 34%), intracranial hemorrhagic events (OR = 0.61; 95% CI, 0.03-10.79; I2 = 62%), morbidity (OR = 0.53; 95% CI, 0.05-5.72; I2 = 86%), and mortality (OR = 1.96; 95% CI, 0.64-5.97; I2 = 0%) between the 2 groups. Subgroup analysis suggested that platelet function testing-guided therapy may contribute to fewer symptomatic thromboembolic events in patients who received stent-assisted coiling (OR = 0.43; 95% CI, 0.18-1.02; I2 = 43%) or a combination of stent-assisted and flow-diverter stent placement (OR = 0.61; 95% CI, 0.36-1.02; I2 = 0%) or who changed from clopidogrel to other thienopyridines (OR = 0.64; 95% CI, 0.40-1.02; I2 = 18%), though the difference did not reach statistical significance. LIMITATIONS: Heterogeneous endovascular treatment methods and adjusted antiplatelet regimens were limitations. CONCLUSIONS: Platelet function testing-guided antiplatelet strategy significantly reduced the incidence of symptomatic thromboembolic events without any increase in the hemorrhagic events for patients undergoing endovascular treatment for intracranial aneurysms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Departments of Pharmacy (X.W., Z.A.).
- Department of Pharmacy (L.L.), Beijing Huairou Hospital, Beijing, China.
- Neurosurgery (Y.W.), Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
- From the Departments of Pharmacy (X.W., Z.A.) anzhuoling@163.com.
Zitieren
APA
Wang, X., Luo, L., Wang, Y., & An, Z. (2023). Effect of Platelet Function Testing Guidance on Clinical Outcomes for Patients with Intracranial Aneurysms Undergoing Endovascular Treatment. American Journal of Neuroradiology. https://doi.org/10.3174/ajnr.a7923
Vancouver
Wang X, Luo L, Wang Y, An Z. Effect of Platelet Function Testing Guidance on Clinical Outcomes for Patients with Intracranial Aneurysms Undergoing Endovascular Treatment. American Journal of Neuroradiology. 2023. doi:10.3174/ajnr.a7923
BibTeX
@article{Wang2023,
author = {Wang, X and Luo, L and Wang, Y and An, Z},
title = {Effect of Platelet Function Testing Guidance on Clinical Outcomes for Patients with Intracranial Aneurysms Undergoing Endovascular Treatment},
journal = {American Journal of Neuroradiology},
year = {2023},
doi = {10.3174/ajnr.a7923}
}
EUVIMED